The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and dose-escalation study of a targeted oncolytic adenovirus, suratadenoturev (OBP-301), in patients with refractory advanced liver cancer: Phase I clinical trial.
 
Jeong Heo
Research Funding - Gilead Sciences; Roche; Yuhan
 
Ja-Der Liang
No Relationships to Disclose
 
Chang Won Kim
No Relationships to Disclose
 
Hyun Young Woo
No Relationships to Disclose
 
I-Lun Shih
No Relationships to Disclose
 
Tung-Hung Su
No Relationships to Disclose
 
Zhong-Zhe Lin
No Relationships to Disclose
 
Stanley Chang
Employment - Medigen Biotechnology Corporation
Leadership - Medigen Biotechnology Corporation
Stock and Other Ownership Interests - Medigen Biotechnology Corporation
 
Yasuo Urata
Employment - Oncolys BioPharma
Leadership - Oncolys BioPharma
Stock and Other Ownership Interests - Oncolys BioPharma
 
Pei-Jer Chen
No Relationships to Disclose